Opyt primeneniya preparata Orsoten (orlistat)u bol'nykh ozhireniem
https://doi.org/10.14341/2071-8713-5278
Abstract
At present, the epidemic of overweight and obesity is one of the most pressing public health problems worldwide.
Pharmacotherapy is often initiated to increase the effectiveness of obesity therapy, including orlistat, which is a long-acting inhibitor of
gastric and pancreatic lipases that reduces splitting and subsequent absorption of fat food. Till the recent time the only available orlistat
preparation was Xenical (F. Hoffman La Roche Ltd, Switzerland). In 2009, in Russia was registered another trade name of drug - Orsoten
(KRKA, Slovenia), which is the first generic drug orlistat. The article shows the results of a study conducted to examine the clinical
equivalence, efficacy and safety of the drug Orsoten compared with Xenical in obese patients.
Pharmacotherapy is often initiated to increase the effectiveness of obesity therapy, including orlistat, which is a long-acting inhibitor of
gastric and pancreatic lipases that reduces splitting and subsequent absorption of fat food. Till the recent time the only available orlistat
preparation was Xenical (F. Hoffman La Roche Ltd, Switzerland). In 2009, in Russia was registered another trade name of drug - Orsoten
(KRKA, Slovenia), which is the first generic drug orlistat. The article shows the results of a study conducted to examine the clinical
equivalence, efficacy and safety of the drug Orsoten compared with Xenical in obese patients.
References
1. Внутренние болезни по Т.Р. Харрисону под редакцией Э. Фаучи, И. Иссельбахера, Ю. Браунвальда, Дж. Уилсона, Дж. Мартина, Д. Каспера, С. Хаузера, Д. Лонго. Изд-во «Практика», Москва, 2002; часть 5, глава 72: С. 530.
2. Goldstein D.J. Beneficial health effects of modest weight loss // Int. J. Obesity, 1992; 16: Р. 397-415.
3. Guerciolini R. Mode of action of orlistat // Int. J. Obesity. 1997; 21 (suppl 3): S. 12-23.
4. Jarl S. Torgeson. Preventing Diabetes in the Obese: The XENDOS Study and Its. Context // Br. J. Diabetes Vasc. Dis., 2004. 4 (1): Р. 22-7.
5. Low S., Chin M.C., Deurenberg-Yap M. Review on epidemic of obesity // Ann. Acad. Med. Singapore. 2009, Jan.; 38(1): Р. 57-9.
6. Zhi J., Melia A.T., Eggers H., et al. Review of limited systemic absorption of orlistat, a lipase inhibitor, in health human volunteers // J. Clin. Pharmacol. 1995; 35: Р. 1103-8.
7. Zhi J., Melia A.T., Guerciolini R., et al. Retrospective population - based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers // Clin. Pharmacol. Ther. 1994; 56: Р. 82-5.
Review
For citations:
, , Opyt primeneniya preparata Orsoten (orlistat)u bol'nykh ozhireniem. Obesity and metabolism. 2010;7(1):46-50. (In Russ.) https://doi.org/10.14341/2071-8713-5278
Views:
3153
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
